Case Study: Leading Pharmaceutical Enterprise achieves faster drug development and a transformed R&ED procurement infrastructure with GEP

How GEP Helped A Pharma Giant Transform R&ED Procurement Infrastructure and Reduce Drug Development Time

A Fortune 200 pharmaceutical company faced a pressing challenge: its research and early development (R&ED) procurement infrastructure was outdated and lacked the technology, data access and processes needed to deliver a seamless, personalized clinical trials journey across pre‑clinical and clinical stages. The firm needed to expand use of real‑world data and AI, enable virtual trials and advanced monitoring, and cut drug development time without losing competitive advantage.

GEP established a Strategic Transactions Group, managed multi‑program requirements, conducted market research and due diligence on 35 vendors, ran RFPs and integrated suppliers offering AI/ML modeling, virtual trial platforms, wearables, organoids and molecular and patient data. Deliverables included 10 master service agreements, 15 one‑time agreements, 21 SOWs, seven SOPs and onboarding job aids—resulting in faster drug development, improved patient outcomes, streamlined vendor management, cost optimization and quicker ramp‑up for R&ED teams.